Soliman Ashraf T, Prabhakaran Nair Arun, Al Masalamani Muna S, De Sanctis Vincenzo, Abu Khattab Mohamad A, Alsaud Arwa E, Sasi Sreethish, Ali Elrazi A, Ola A Hassan, Iqbal Fatima M, Nashwan Abdulqadir J, Fahad Jesin, El Madhoun Ihab, Yassin Mohamed A
Pediatric and Endocrinology, Hamad General Hospital, Doha, Qatar .
Communicable Disease Center (CDC), Hamad Medical Corporation (HMC), Doha, Qatar.
Acta Biomed. 2020 Sep 7;91(3):e2020010. doi: 10.23750/abm.v91i3.10214.
There is a scarcity of data regarding the effect of Type 2 diabetes mellitus (T2DM) and associated comorbidities on the clinical presentation and outcome of symptomatic patients with -COVID-19 infection in comparison with non-diabetic patients.
We described and compared the clinical presentation and radiological and hematological data of a cohort of symptomatic COVID19 positive T2DM diabetic patients (n = 59) versus another cohort of non-diabetic symptomatic COVID19 positive patients (n =244) diagnosed at the same time from January 2020 to May 2020. Associated comorbidities were -assessed, and the Charlson Comorbidity Index was calculated. The outcomes including duration of hospitalization, duration of Intensive Care Unit (ICU) stay, duration of mechanical ventilation, and duration of O2 -supplementation were assessed.
Prevalence of T2DM in symptomatic COVID19 positive patients was 59/303 (=19.5%). Diabetic patients had higher prevalence of hypertension, chronic kidney disease (CKD) and cardiac dysfunction [coronary heart disease (CHD)], and congestive heart failure (CHF). Charlson Comorbidity score was significantly higher in the T2DM patients (2.4± 1.6) versus the non-diabetic -patients (0.28 ± 0.8; p: < 0.001). Clinically and radiologically, T2DM patients had significantly higher percentage of pneumonia, severe pneumonia and ARDS versus the non-diabetic patients. Hematologically, diabetic patients had significantly higher C-reactive protein (CRP), higher absolute neutrophilic count (ANC) and lower counts of lymphocytes and eosinophils compared to non-diabetic patients. They had significantly higher systolic and diastolic blood pressures, longer duration of hospitalization, ICU stay, mechanical ventilation and oxygen therapy. CRP was correlated significantly with the duration of stay in the ICU and the duration for oxygen supplementation (r = 0.37 and 0.42 respectively; p: <0.01).
T2DM patients showed higher inflammatory response to COVID 19 with higher absolute neutrophilic count (ANC) and CRP with lower lymphocytic and eosinophilic counts. Diabetic patients had more comorbidities and more aggressive course of the disease with higher rate of ICU admission and longer need for hospitalization and oxygen use.
与非糖尿病患者相比,关于2型糖尿病(T2DM)及其相关合并症对有症状的COVID-19感染患者临床表现和预后影响的数据较少。
我们描述并比较了一组有症状的COVID-19阳性T2DM糖尿病患者(n = 59)与另一组同时在2020年1月至2020年5月确诊的非糖尿病有症状COVID-19阳性患者(n = 244)的临床表现、放射学和血液学数据。评估相关合并症,并计算查尔森合并症指数。评估包括住院时间、重症监护病房(ICU)住院时间、机械通气时间和吸氧时间在内的预后情况。
有症状的COVID-19阳性患者中T2DM的患病率为59/303(=19.5%)。糖尿病患者高血压、慢性肾脏病(CKD)和心脏功能障碍[冠心病(CHD)]以及充血性心力衰竭(CHF)的患病率更高。T2DM患者的查尔森合并症评分(2.4±1.6)显著高于非糖尿病患者(0.28±0.8;p:<0.001)。在临床和放射学方面,与非糖尿病患者相比,T2DM患者肺炎、重症肺炎和急性呼吸窘迫综合征(ARDS)的比例显著更高。在血液学方面,与非糖尿病患者相比,糖尿病患者的C反应蛋白(CRP)显著更高,绝对中性粒细胞计数(ANC)更高,淋巴细胞和嗜酸性粒细胞计数更低。他们的收缩压和舒张压显著更高,住院时间、ICU住院时间、机械通气时间和吸氧治疗时间更长。CRP与ICU住院时间和吸氧时间显著相关(分别为r = 0.37和0.42;p:<0.01)。
T2DM患者对COVID-19表现出更高的炎症反应,绝对中性粒细胞计数(ANC)和CRP更高,淋巴细胞和嗜酸性粒细胞计数更低。糖尿病患者合并症更多,疾病进程更严重,ICU入院率更高,住院和吸氧需求时间更长。